Interview with Sir Andrew Dillon, Chief Executive, National Institute for Health…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Address: National Institute for Health and Clinical Excellence
1st Floor
10 Spring Gardens
London
SW1A 2BU
Tel: +44 (0)845 003 7780
The National Institute for Health and Clinical Excellence (NICE) is an NHS organisation based in London and Manchester. NICE was set up on 1 April 1999 to ensure everyone has equal access to medical treatments and high quality care from the NHS – regardless of where they live in England and Wales.
Today NICE is recognised as being a world leader in setting standards for high quality healthcare and are the most prolific producer of clinical guidelines in the world. It also produces public health recommendations on how to help improve people’s health and prevent disease. These are aimed not just at the NHS but at local authorities and all those with a remit for improving people’s health in the public, private, community and voluntary sectors.
Topics covered by NICE’ guidance range from helping people to stop smoking and encouraging them to be more physically active through to the treatment of cancer, diabetes, musculoskeletal conditions and mental health problems. NICE also makes recommendations on the use of a range of drugs.
All its recommendations are devised by independent committees. NICE’s Citizens Council is the UK’s first advisory body made up entirely of members of the public.
NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health.
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
What is the importance of the UK operations for Takeda worldwide? Our UK operation was established in 1997 and is relatively younger than other affiliates in Europe such as Takeda…
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
You used to be the Managing Director of Ranbaxy in China. Having moved to a directorship in the UK, what professional challenges do you see in this country that distinguish…
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you in BMS? Before joining…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan…
This year’s Q1 results for Novo Nordisk were extremely positive with a 23% increase in profit. While this growth was mostly driven by the US and emerging markets, what does…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was put in place last…
It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some…
See our Cookie Privacy Policy Here
